Detalhe da pesquisa
1.
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
Eur Radiol
; 33(1): 512-522, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35864351
2.
Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
J Formos Med Assoc
; 121(8): 1371-1383, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35400583
3.
Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma.
Int J Mol Sci
; 22(23)2021 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34884684
4.
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Liver Int
; 39(11): 2184-2189, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31400295
5.
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma.
J Gastroenterol Hepatol
; 31(7): 1336-41, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26860846
6.
It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade.
J Formos Med Assoc
; 120(1 Pt 1): 1-4, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32660891
7.
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.
Clin Mol Hepatol
; 29(2): 230-241, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36710607
8.
Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy.
Cancers (Basel)
; 13(20)2021 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34680292
9.
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma.
J Hepatocell Carcinoma
; 8: 809-822, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34336726
10.
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
J Hepatol
; 52(1): 88-95, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19913321
11.
Novel systemic therapy for hepatocellular carcinoma.
Hepatol Int
; 14(5): 638-651, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32661949
12.
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment.
Liver Cancer
; 8(2): 110-120, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31019901
13.
Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study.
Sci Rep
; 9(1): 9478, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31263137
14.
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma.
Expert Rev Gastroenterol Hepatol
; 13(7): 615-621, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31132887
15.
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Liver Cancer
; 8(6): 480-490, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31799205
16.
Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure.
Liver Cancer
; 7(2): 205-208, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29888209
17.
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Clin Cancer Res
; 16(21): 5189-99, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20884624